We reactivate the body’s own cells to fight disease
We are a biotechnology company focused on restoring cells’ youthful vigor to repair damage caused by the aging process.
Using a proprietary ERA™ Platform, we develop mRNA medicines that are specially formulated to instruct specific cells in the body to fight disease or repair damaged tissue. We do this by reprogramming the epigenome to restore cell function that people often lose as they age
This approach can be used to revitalize different cells throughout the body – we are researching its applicability across multiple therapeutic areas, including dermatologic conditions, immunology, osteoarthritis and ophthalmology.
Executive Team
A veteran of Fortune 500 enterprises and co-founder of three Silicon Valley startups, Anja has guided the evolution of companies and their products, taking companies public, repositioning enterprises, and managing development teams, clinical trials and partnerships. Anja’s successes have enabled four companies to sell themselves or their product lines to larger corporations. She received her bachelor’s degree from the University of South Carolina and a certificate of International Trade from the University of Paris, Sorbonne.
The technology at the foundation of Turn’s ERA™ platform was developed and patented in Vittorio’s Stanford University lab. An expert in stem cell biology and epigenetic reprogramming, he has worked in some of the world’s most prestigious academic institutions and is on the faculty of Stanford School of Medicine. He received his bachelor’s degree and doctorate from the University of Pavia and completed post-doctoral work at the Max Planck Institute for Molecular Biomedicine in Germany and Stanford.
An entrepreneur, philanthropist and investor, Sergio has worked with several biotechnologies designed to increase healthy lifespan. He is a senior advisor to numerous longevity biotech companies, helping them to evolve from academic organizations to commercial enterprises. Sergio is also managing director of the Methuselah Fund, one of the first longevity focused investor groups. He received his bachelor’s degree from the University of Maryland and a genetics and genomics certificate from Stanford University.
With more than two decades of financial leadership experience in the pharmaceutical industry, Ric understands the nuances of financial management, fundraising, road shows and initial public offerings. He has helped to guide six pharmaceutical companies – both large and small – as chief financial officer and managed balance sheets of up to $2 billion. He is also the Universal Insurance Holdings board audit committee chair. Ric received his bachelor’s degree from Arizona State University.
A corporate and patent attorney who completed postdoctoral work at Harvard Medical School, the VA Boston Healthcare System and Kyoto University, Devang has novel and practical perspectives on how to protect intellectual property here and internationally. As a U.S. patent examiner, he granted more than 130 pharmaceutical and biotechnology patents in a decade. He has also advised Global 500 companies, domestic and international startups, venture capital firms and universities on intellectual property and business issues.
A CMC expert who has founded two pharmaceutical companies and shaped the direction of several others, Mouhannad is an expert in CMC, the discipline of ensuring a therapeutic is safe, effective and consistent. He is responsible for planning and managing pharmaceutical, CMC analytical and pre-clinical activites. He received his doctorate in pharmaceutical science from the University of Kiel in Germany and completed post-doctoral work at the University of Kansas.
A veteran executive and dealmaker, Marie-Louise has helped companies develop license and distribution agreements and partnerships to boost sales and profitability. She has worked with multinational corporations like Royal Philips Electronics, Reed Elsevier and Aon Risk Solutions, as well as venture-backed biotechs. She serves on the supervisory boards of Royal Asscher Diamond Company and Plasmacure, a medical startup. Marie-Louise received her Economics degree from Fontys University and completed executive leadership studies at Harvard Business School, Babson College and the Rotterdam School of Management.
A proven drug developer with 30 years of pharmaceutical industry experience, Hans has helped bring 10 products to market, been involved with 13 INDs and holds 21 patents. This proficiency in commercializing laboratory science will be critical to his role leading the development of regenerative medicine therapies in dermatology, immunology, and ophthalmology. The veteran of more than a dozen dermatology and Immunology companies received his doctorate in Pharmaceutical Sciences from the University of Leiden in the Netherlands.
Scientific Advisory Board
The technology at the foundation of Turn’s ERA™ platform was developed and patented in Vittorio’s Stanford University lab. An expert in stem cell biology and epigenetic reprogramming, he has worked in some of the world’s most prestigious academic institutions and is on the faculty of Stanford School of Medicine. He received his bachelor’s degree and doctorate from the University of Pavia and completed post-doctoral work at the Max Planck Institute for Molecular Biomedicine in Germany and Stanford.
A research scientist and serial entrepreneur who has founded or co-founded three companies, Marco is an expert on aging, regenerative medicine, rejuvenation, stem cell biology and bioengineering. Most of his work has focused on developing therapies for the treatment of age-related disease. Marco received a bachelor’s degree from Università di Bologna, a doctoral degree from Università degli Studi di Padova and completed post-doctoral work at Stanford University.
A professor at Stanford University School of Medicine, the director of Glenn Laboratories for the Biology of Aging at Stanford, deputy director of the Stanford Center on Longevity and chief of neurology at VA Palo Alto Health Care System, Thomas is recognized as a leading authority on the mechanisms of stem cell aging. He received his bachelor’s and doctoral degrees from Harvard and obtained his medical degree from Harvard Medical School.
As co-director of the Institute of Stem Cell Biology and Regenerative Medicine and program director of Regenerative Medicine at Stanford University, Michael is an expert on wound healing, developmental biology, tissue engineering and stem cell biology. He earned his bachelor’s degree at Michigan State University and his medical degree at Harvard Medical School. He completed post-graduate work at the University of California San Francisco and obtained a master’s degree in business administration from the combine program of University of California Berkley and Columbia University.
Medical Advisory Board
A board-certified dermatologist and former faculty member of the Stanford University School of Medicine, Scott has nearly three decades of clinical and research experience. He has consulted with biopharmaceutical industry companies, authored or co-authored more than 30 peer-reviewed papers and secured several patents in the biomedical field. He received his medical degree from the University of Southern California and did his residency at Stanford University.
Board certified in oncology and pediatrics, Kevin serves as Immune Effector Cell Program Director and interim co-director of the Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center’s GMP investigational cell therapy facility, where he develops novel cellular treatments for malignancies affecting children and young adults who do not respond to standard therapies. He specializes in the use of CAR T cell therapy to deliver more effective treatment options for cancer patients and avoid the long-term side effects that often result from conventional treatments.
A board-certified dermatologist and dermatophatologist, Michael is on the faculty of the University of Nevada Reno School of Medicine and is currently managing several studies at the Skin Cancer and Dermatology Institute in Reno. His clinical experiences have taken him to Europe, Central and South America and he has authored or co-authored more than a dozen publications. Michael received his bachelor’s degree from the University of Michigan, his medical degree from the University of Texas and completed his residency at Wright State University in Ohio.
Board certified in oncology and pediatrics, Joseph is experienced in using stem cell/bone marrow transplantation and cellular/gene therapies to cure non-cancerous diseases. He leads the Primary Immunodeficiency and Immune Dysregulation Program at Memorial Sloan Kettering Cancer Center, where he cares for patients with hard-to-treat immune dysfunctions or inherited immune deficiencies. Joseph has broad clinical expertise with immune dysregulations, bone marrow failure syndromes, and non-malignant blood disorders. He has extensively researched new ways to personalize transplantation to achieve a precise cure with minimal side effects.
A board-certified ophthalmologist, Albert serves as director of Oculoplastics Research at Stanford University and leads its Ophthalmic Stem Cell and Regenerative Medicine Laboratory, where he is developing cutting edge treatments for vision loss and eye disease. He has previously developed stem cell therapies to treat corneal blindness and regenerate the ocular surface. Albert authored or co-authored more than 40 publications. He received his bachelor’s degree from Yale University, completed his medical training and received a doctoral degree from the University of Washington.
Executive Advisors
A serial biomedical entrepreneur who has developed novel, effective therapies for diverse medical conditions, Kin’s research and product development experience spans biomedical sciences, medical devices, lasers/photonics and semiconductors. He has therapeutic experience in dermatology, cardiology, urology and ophthalmology, and has developed numerous products and expanded pipelines in pharmaceuticals and medical devices. Kin holds a Ph.D. in electrical and computer engineering from the University of Texas at Austin, where he also achieved his bachelors and masters degrees.
With more than 30 years of accomplishment in biopharmaceutical drug and contract research service, Brian has unparalleled drug discovery and development experience in multiple therapeutic areas. As chief scientific officer at the Carolina Longevity Institute, he also understand the challenges posed by diseases of aging, including osteoarthritis, oncology, dementia and metabolic diseases. Brian received his bachelors and masters degrees from Villanova University in Pennsylvania and his doctorate from George Washington University Medical Center in Washington, D.C.
Former Turn CEO, Gary is executive chairman and co-founder of Oisín Biotechnologies, which is researching ways to mitigate the effects of age-related diseases by addressing damage created by the aging process. Gary is active in several non-profits focused on age-related disease, including the SENS Research and Methuselah foundations. A serial entrepreneur, he earlier successfully launched and grew several companies focused on commercial space travel. Gary remains involved in the field as president of the Space Studies Institute.
